BOSTON, June 21, 2023 /PRNewswire/ -- Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company today announced initiation of Part 2 of the RECONNOITER Phase 2 study, evaluating Profervia®, a once-daily novel, oral calcium-channel antagonist (CCB) in patients with SSc and Raynaud's phenomenon(SSc-RP). The study is a double-blind, placebo-controlled, randomized, prospective crossover study design which will take approximately 10 months to complete.
The national drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 22 formulations under Drugs Prices Control Order (DPCO), 2013 in related notification dated May 02, 2019.